← Leaderboards
Zahid H Siddik
University Of Texas Md Anderson Can Ctr
$6,100,049
Attributed
$6,100,049
Total exposure
6
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $583.3K · FY2007–25$1M$750K$500K$250K$0
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$6,100,049 · 6
By mechanism
R01$5,683,506 · 5
R21$416,543 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of Texas Md Anderson Can Ctr
Same institution · by research overlap
- David G. Johnson$18,592,669
- Mien-Chie Hung$10,660,923
- Hagop Kantarjian$4,345,422
- Kun-Sang Chang$3,987,358
- Colin P Dinney$4,248,660
Others in their field
Top investigators on “Neoplastic Cell”
- David Heimbrook · Leidos Biomedical Research, Inc.$139,710,838
- Gregory H Reaman · National Childhood Cancer Foundation$31,993,642
- Bruce W Stillman · Cold Spring Harbor Laboratory$25,455,900
- Ralph Parchment · Leidos Biomedical Research, Inc.$25,266,647
- Andrea Califano · Columbia University Health Sciences$22,374,316
- Wendell A Lim · University Of California, San Francisco$22,334,734
Research focus
Neoplastic CellAnalogPlatinumMalignant NeoplasmsTumorCellsPharmaceutical PreparationsResistanceResponseMutantCisplatinTp53 GeneProteinsPathway InteractionsOxaliplatinBaseComplexCell CycleDna DamagePreventDesignKnock-OutPhosphotransferasesDown-Regulation
Grant awards (22)
Targeting MDM4 in Rare Refractory Ovarian Cancer Sub-Types$227,205
R21 · FY2025 · CA · contact PI
Targeting MDM4 in Rare Refractory Ovarian Cancer Sub-Types$189,338
R21 · FY2024 · CA · contact PI
Cell Cycle Blockade and Therapeutic Sensitization$366,000
R01 · FY2021 · CA · contact PI
Cell Cycle Blockade and Therapeutic Sensitization$366,000
R01 · FY2020 · CA · contact PI
Cell Cycle Blockade and Therapeutic Sensitization$355,019
R01 · FY2019 · CA · contact PI
Cell Cycle Blockade and Therapeutic Sensitization$366,000
R01 · FY2018 · CA · contact PI
Cell Cycle Blockade and Therapeutic Sensitization$366,000
R01 · FY2017 · CA · contact PI
Targeted Development of Platinum Drugs$327,850
R01 · FY2015 · CA · contact PI
Targeted Development of Platinum Drugs$318,015
R01 · FY2014 · CA · contact PI
Targeted Development of Platinum Drugs$308,179
R01 · FY2013 · CA · contact PI
Targeted Development of Platinum Drugs$327,850
R01 · FY2012 · CA · contact PI
Targeted Development of Platinum Drugs$327,850
R01 · FY2011 · CA · contact PI
Checkpoint Response and Platinum Drug Sensitivity$255,440
R01 · FY2011 · CA · contact PI
Checkpoint Response and Platinum Drug Sensitivity$263,340
R01 · FY2010 · CA · contact PI
Checkpoint Response and Platinum Drug Sensitivity$263,340
R01 · FY2009 · CA · contact PI
Checkpoint Response and Platinum Drug Sensitivity$263,340
R01 · FY2008 · CA · contact PI
Checkpoint Response and Platinum Drug Sensitivity$263,340
R01 · FY2007 · CA · contact PI
CIRCUMVENTION OF CISPLATIN RESISTANCE$216,203
R01 · FY2002 · CA
CIRCUMVENTION OF CISPLATIN RESISTANCE$209,907
R01 · FY2001 · CA
MECHANISTIC DEVELOPMENT OF PLATINUM BASED DRUGS$160,356
R01 · FY2001 · CA
CIRCUMVENTION OF CISPLATIN RESISTANCE$203,793
R01 · FY2000 · CA
MECHANISTIC DEVELOPMENT OF PLATINUM BASED DRUGS$155,684
R01 · FY2000 · CA